Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Endometrial Serous Adenocarcinoma Clinical Trial

Official title:

Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02501954
• Other study ID #: 15-07
• Status: Completed
• Phase: Phase 3
• Start date: March 2015
• Est. completion date: November 2023

Study information

• Verified date: December 2023
• Source: Women's Cancer Care Associates, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine if treatment with cisplatin and radiation followed by carbo and taxol reduces the rate of recurrence when compared to sandwich therapy.

Description:

To determine if treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for 4 cycles (experimental arm) reduces the rate of recurrence (increases recurrence-free survival) when compared to sandwich therapy (control arm).

To determine if treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for 4 cycles (experimental arm) reduces the rate of death (increases survival) when compared to sandwich therapy (control arm).

To compare the regimens with respect to tolerability and acute and late adverse effects of therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: November 2023
• Est. primary completion date: November 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients with Surgical Stage III or IVA endometrial carcinoma per FIGO 2009 staging criteria, including clear cell and serous papillary and undifferentiated carcinomas.

• Surgical Stage III disease includes those patients with positive adnexa, parametrial involvement, tumor invading the serosa, positive pelvic and/or para-aortic nodes, or vaginal involvement.

• Surgical Stage IVA includes patients with bladder or bowel mucosal involvement, but no spread outside the pelvis.

• Patients with FIGO 2009 surgical Stage I or II endometrial clear cell or serous carcinoma and with positive peritoneal cytology.

• Surgery must have included a hysterectomy and bilateral salpingooophorectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional.

• Patients with a GOG Performance Status of 0, 1, or 2.

• Patients with adequate organ function, reflected by the following parameters:

WBC = 3000/mcl Absolute neutrophil count (ANC) = 1500/mcl Platelet count = 100,000/mcl SGOT, SGPT, and alkaline phosphatase = 2.5 X upper limit of normal (ULN) Bilirubin = 1.5 X ULN Creatinine = institutional ULN

• Patients must be 18 years of age or older.

• Entry into the study is limited to no more than 8 weeks from the date of surgery.

Exclusion Criteria:

• Patients with carcinosarcoma.

• Patients with recurrent endometrial cancer.

• Patients with residual tumor after surgery (any single site) exceeding 1 cm in maximum dimension.

• Patients who have had pelvic or abdominal radiation therapy.

• Patients with positive pelvic washings as the only extra-uterine disease are NOT eligible if the histology is other than clear cell or papillary serous carcinoma.

• Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of active malignancy within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.

• Patients with a history of serious co-morbid illness or uncontrolled illnesses that would preclude protocol therapy.

• Patients with an estimated survival of less than three months.

• Patients with FIGO 2009 Stage IVB endometrial cancer.

• Patients with parenchymal liver metastases.

• Patients who have received prior chemotherapy for endometrial cancer.

• Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment.

Related Conditions & MeSH terms

• Adenocarcinoma
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Stage IIIA Uterine Corpus Cancer
• Stage IIIB Uterine Corpus Cancer
• Stage IIIC Uterine Corpus Cancer
• Stage IVA Uterine Corpus Cancer

Intervention

Drug:
• Cisplatin
Given IV
• Carboplatin
Given IV
• Paclitaxel
Given IV

Radiation:
• Radiation Therapy
Undergo Radiation Therapy

Locations

Country	Name	City	State
Canada	CHUM Hopital Notre-Dame	Montréal	Quebec
United States	Women's Cancer Care Associates, LLC	Albany	New York
United States	Greater Baltimore Medical Center	Baltimore	Maryland
United States	The Ohio State University	Columbus	Ohio
United States	Gunderson Lutheran Medical Foundation	La Crosse	Wisconsin
United States	Atlantic Health	Morristown	New Jersey
United States	Munson Health Care	Traverse City	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Women's Cancer Care Associates, LLC

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of acute and adverse effects as graded by the NCI Common Toxicity Criteria for Adverse Events version (CTCAE) version 4.0		From study entry through completion of study treatment, assessed for 1 year.
Primary	Recurrence-free survival (RFS)	RFS will be assessed by radiology tests, patient's clinical symptoms or physical exam.	From study entry until disease recurrence, death, or date of last contact, assessed up to 8 years
Secondary	Overall survival (OS)	OS assessed by the contact with patient in person or by telephone	from study entry to death or date of last contact, assessed up to 8 years